Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin

Sunil Parikh  
*University of California - San Francisco*

Jun Liu  
*Washington University School of Medicine in St. Louis*

Puran Sijwali  
*University of California - San Francisco*

Jiri Gut  
*University of California - San Francisco*

Daniel E. Goldberg  
*Washington University School of Medicine in St. Louis*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)
Antimalarial Effects of Human Immunodeficiency Virus Type 1 Protease Inhibitors Differ from Those of the Aspartic Protease Inhibitor Pepstatin

Sunil Parikh, Jun Liu, Puran Sijwali, Jiri Gut, Daniel E. Goldberg and Philip J. Rosenthal


Updated information and services can be found at:
http://aac.asm.org/content/50/6/2207

REFERENCES

This article cites 15 articles, 10 of which can be accessed free at: http://aac.asm.org/content/50/6/2207#ref-list-1

CONTENT ALERTS

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»
Antimalarial Effects of Human Immunodeficiency Virus Type 1 Protease Inhibitors Differ from Those of the Aspartic Protease Inhibitor Pepstatin

Sunil Parikh,¹* Jun Liu,² Puran Sijwali,¹ Jiri Gut,¹ Daniel E. Goldberg,² and Philip J. Rosenthal¹

Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California,¹ and Department of Medicine and Department of Molecular Microbiology, Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, Missouri²

Received 6 January 2006/Returned for modification 30 January 2006/Accepted 6 March 2006

Human immunodeficiency virus type 1 protease inhibitors (HIVPIs) and pepstatin are aspartic protease inhibitors with antimalarial activity. In contrast to pepstatin, HIVPIs were not synergistic with a cysteine protease inhibitor or more active against parasites with the cysteine protease falcipain-2 knocked out than against wild-type parasites. As with pepstatin, HIVPIs were equally active against wild-type parasites and against parasites with the food vacuolar plasmepsin aspartic proteases knocked out. The antimalarial mechanism of HIVPIs differs from that of pepstatin.

Human immunodeficiency virus type 1 (HIV-1) and malaria are coendemic throughout much of the developing world. HIV-1 expresses an aspartic protease, which is an important drug target (3). In addition to their important antiretroviral activity, HIV-1 protease inhibitors (HIVPIs) are active against Plasmodium falciparum in vitro and against rodent malaria parasites in murine models (7, 9, 13). The predicted targets of these inhibitors are plasmepsins, a family of aspartic proteases of malaria parasites. A number of plasmepsins act in concert with falcipain cysteine proteases and other enzymes to hydrolyze hemoglobin in the P. falciparum food vacuole (5, 8). Several HIVPIs inhibit the food vacuole protease plasmepsin II (7) and a homologous protease of the rodent parasite Plasmodium chabaudi (6). Pepstatin, the most-studied aspartic protease inhibitor, also exhibits activity against cultured malaria parasites and inhibits several plasmepsins (2, 6). As the antimalarial activity of HIVPIs may have important implications in areas where those treated for HIV-1 infection are at risk of malaria, and as both HIVPIs and pepstatin may serve as leads for new antimalarial agents, it was of interest to compare their antimalarial mechanisms of action.

Insight into the antimalarial mechanisms of protease inhibitors came from studies that showed that cysteine protease inhibitors [N-(trans-epoxysuccinyl)-l-leucine-4-guanidinobutylamide (E-64)] and aspartic protease inhibitors (pepstatin) display marked synergy against malaria parasites (1, 10). Further supporting an important interaction between these two classes of proteases, pepstatin had markedly enhanced activity against P. falciparum parasites in which the gene for the cysteine protease falcipain-2 was disrupted (11). It was of interest to determine if HIVPIs had effects similar to those of pepstatin.

We evaluated the HIVPI lopinavir for synergy with E-64. P. falciparum (W2 strain) parasites were cultured in RPMI medium supplemented with 10% serum and synchronized with 5% D-sorbitol as previously described (11). Ring stage parasites were incubated with study drugs (0.039 to 10 μM, from stock solutions concentrated 1,000-fold in dimethyl sulfoxide [DMSO]) or with equivalent concentrations of DMSO for 48 h, fixed with 1% formaldehyde in phosphate-buffered saline for 48 h, and labeled with 1 nM YOYO-1 dye (Molecular Probes) in 0.1% Triton X-100 in phosphate-buffered saline. Parasitemias were determined from dot plots acquired with a FACSort flow cytometer, and 50% inhibitory concentration (IC50) values were calculated as previously described (11, 12). Potential synergy was evaluated as the sum of the fractional inhibitory concentrations (sum FIC) by the following equation: sum FIC = [(IC50 drug A in combination)/(IC50 drug A alone)] + [(IC50 drug B in combination)/(IC50 drug B alone)]. The sum FIC value for lopinavir and E-64 was 2.04 ± 0.48 (mean ± standard deviation of results from two experiments, each done in triplicate). Thus, lopinavir and E-64 (Sigma-Aldrich) showed no evidence of synergism, but rather borderline antagonism. In contrast, E-64 and pepstatin have shown marked synergy with a sum FIC value of 0.54 ± 0.16 (10).

To further characterize the antimalarial mechanism of HIVPIs, we tested the compounds against P. falciparum parasites with disrupted food vacuole proteases. For plasmepsin knockout parasites, previously described 3D7 strain parasites were used (5). For falcipain-2 knockout parasites, procedures very similar to those previously described were used (11). Briefly, 3D7 strain parasites were transfected with the pHKΔFP2 plasmid, selected with WR99210 until integration of the plasmids was detected, enriched for recombinant parasites through negative selection with ganciclovir, and cloned to obtain pure recombinant parasites. Wild-type 3D7 and plasmepsin knockout parasites were incubated in microwell cultures in the presence of serial dilutions of lopinavir, ritonavir, and saquinavir (0.025 to 150 μM, from 1,000-fold-concentrated
stocks in DMSO) or with equivalent concentrations of DMSO for 44 h, beginning at the ring stage, and then 0.5 μCi of [3H]hypoxanthine (178.7 Ci/mmol; Perkin Elmer) was added. The incubation was continued for 16 h, the parasites were harvested, the hypoxanthine uptake rates of treated and control parasites were compared, and IC50 values were generated as previously described (5). The antimalarial activities of seven HIVPIs against 3D7 wild-type and falcipain-2 knockout parasites were evaluated by assessing the fluorescence of YOYO-1-stained parasites and determining IC50 values using fluorescence-activated cell sorter-based analysis as described above (11, 12).

HIVPIs had similar activities against control, plasmepsin knockout (Table 1), and falcipain-2 knockout (Table 2) parasites. Discrepancies between reported IC50 values in Tables 1 and 2 likely reflect differences between the [3H]hypoxanthine uptake and fluorescence-activated cell sorter-based assay methods. Considering the actions of other protease inhibitors, E-64 was about twice as active against falcipain-2 knockout and plasmepsin knockout parasites as it was against control parasites, as previously described (5). Pepstatin (Sigma-Aldrich) was about equally active against control and plasmepsin knockout parasites but was much more active against falcipain-2 knockout parasites, all consistent with prior findings (5, 11).

Our results identify major differences between the antimalarial activities of pepstatin and HIVPIs. Pepstatin, the most widely available broadly active aspartic protease inhibitor (3), inhibits multiple plasmepsins and rapidly kills cultured parasites, but its antimalarial mechanism of action is uncertain. For both pepstatin and HIVPIs, activities were similar against wild-type and plasmepsin knockout parasites. These results suggest the functional redundancy of plasmepsins but do not shed light on the mechanism of HIVPIs. In contrast, the activities of pepstatin and HIVPIs differed markedly when evaluated for antimalarial synergy with the cysteine protease inhibitor E-64 or for activity against falcipain-2 knockout parasites. Pepstatin shows strong synergy with cysteine protease inhibitors (10), and it is remarkably more potent against falcipain-2 knockout parasites than against wild-type parasites (11). These results suggest important biological interactions between falcipains and plasmepsins. Surprisingly, the HIVPIs were not synergistic with E-64 and were not more active against falcipain-2 knockout parasites than against wild-type parasites. Thus, although we cannot yet identify specific biological targets for either pepstatin or HIVPIs in malaria parasites, our results strongly suggest that the compounds act differently.

*P. falciparum* encodes 10 predicted aspartic protease genes (14). In addition to the four food vacuole plasmepsins (I to IV), another quite different aspartic protease, plasmepsin V, was recently characterized (4). This protease is not located in the food vacuole and does not bind pepstatin. The HIV-1 protease is also quite different from the food vacuole plasmepsins (15). These structural differences may offer insight into the differential effects of the HIVPIs and pepstatin. Previously we showed that HIVPIs inhibit recombinant plasmepsin II (7), but the intracellular target of these inhibitors is unknown. Thus, pepstatin may target food vacuole plasmepsins, which are dependent on food vacuole cysteine proteases for maximal activity, while HIVPIs may target other aspartic proteases, such as plasmepsin V. In addition to differential inhibition of parasite proteases, various effects may be due to differential access to the food vacuole or other cellular compartments. Alternatively, either pepstatin or HIVPIs might exert antimalarial effects that are unrelated to protease inhibition. Our results do not yet identify a specific mechanism of action for HIVPIs, but they offer the surprising finding that HIVPIs do not, as would have been predicted, act in the same manner as pepstatin. Further research into the precise mode of action of HIVPIs and other antimalarial aspartic protease inhibitors is warranted to provide insight into the development of protease inhibitors as new antimalarial drugs and to understand the means by which antiretroviral drugs may offer protection against malaria.

We thank members of the Rosenthal and Goldberg laboratories for their expert technical assistance. The following protease inhibitors were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: lopinavir, ritonavir, saquinavir (as free base), atazanavir, indinavir, nelfinavir, and amprenavir. *P. falciparum* strains were obtained from the Malaria Reference Reagent Center (Manassas, Va).

Financial support was provided by the National Institutes of Health. P.J.R. is a Doris Duke Charitable Foundation Distinguished Clinical Scientist.

REFERENCES


---

**TABLE 1. Activity of HIV-1 protease inhibitors against P. falciparum plasmepsin knockout parasites**

<table>
<thead>
<tr>
<th>Drug</th>
<th>IC50 (μM) for <em>P. falciparum</em></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Wild type</td>
</tr>
<tr>
<td>Lopinavir</td>
<td>12.2 ± 0.3</td>
</tr>
<tr>
<td>Ritonavir</td>
<td>12.2 ± 0.4</td>
</tr>
<tr>
<td>Pepstatin</td>
<td>3.0 ± 0.4</td>
</tr>
</tbody>
</table>

*IC50 data are means ± standard deviations of results from three experiments. Abbreviations: PMP, plasmepsin; KO, knockout; HAP, histspecific protease.*